How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

Future Oncology

Volumn 9, Issue 6, 2013, Pages 825-829

  Lindsay, Colin R ^a   Roxburgh, Patricia ^a   Graham, Janet ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

cancer; cetuximab; colorectal; irinotecan; oxaliplatin

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RAS PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG USE; HUMAN; METASTATIC COLORECTAL CANCER; MUTANT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84878487919     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.60     Document Type: Article

References (15)

1. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
2. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
3. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 (17), 1757-1765 (2008).
4. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fuoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311-2319 (2008).
5. Au HJ, Karapetis CS, O'Callaghan CJ et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specifc results of the NCIC CTG and AGITG CO.17 Trial. J. Clin. Oncol. 27(11), 1822-1828 (2009).
6. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fuorouracil, and leucovorin as frst-line treatment for metastatic colorectal cancer: updated ana lysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29 (15), 2011-2019 (2011).
7. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fuorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in frst-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30(15), 1755-1762 (2012).
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
9. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
10. Bokemeyer C, Bondarenko I, Hartmann JT et al. Effcacy according to biomarker status of cetuximab plus FOLFOX-4 as frst-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 22(7), 1535-1546 (2011).
11. Pazdur R. Response rates, survival, and chemotherapy trials. J. Natl Cancer Inst. 92, 1552-1553 (2000).
12. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized Phase 2 trial. Lancet Oncol. 11(1), 38-47 (2010).
13. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based frst-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized Phase 3 MRC COIN trial. Lancet 377(9783), 2103-2114 (2011).
14. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fuorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as frst-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
15. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as frst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).